Solacyl 100% Powder 1Kg

Target species Cattle (calves) and pigs. Indications for use Calves: Supportive treatment of pyrexia in acute respiratory disease, in combination with appropriate (e.g. anti-infective) therapy if necessary. Pigs: For the treatment of inflammation in combination with concurrent antibiotic therapy. Contraindications Do not administer in case of severe hypoproteinaemia, liver and kidney disorder. Do not administer in case of gastrointestinal ulcerations and chronic gastrointestinal disorders. Do not administer in case of malfunction of the haemopoietic system, coagulopathy, haemorrhagic diathesis. Do not use sodium salicylates in neonates or calves less than 2 weeks of age. Do not use in piglets of less than 4 weeks of age. Do not use in animals with known hypersensitivity to sodium salicylate. Special precautions for use in animals Given that sodium salicylate may inhibit clotting of blood, it is recommended that elective surgery should not be performed on animals within 7 days after the end of treatment. Special precautions to be taken by the person administering the veterinary medicinal product to animals People with known hypersensitivity to sodium salicylate or related substances (e.g. aspirin) should avoid contact with the veterinary medicinal product. Irritation of the skin, eyes and respiratory tract might occur. During preparation and mixing of the product, direct contact with the skin and eyes, and inhalation of the powder should be avoided. It is recommended to wear gloves, safety glasses and a dust mask. In case of accidental dermal exposure wash skin immediately with water. In the event of accidental eye contact, the user is advised to wash the eye with plenty of water for 15 minutes, and seek medical advice if irritation persists. During administration of medicated water or milk (replacer) to the animals, skin contact should be prevented by wearing gloves. Wash accidentally exposed skin immediately with water. Adverse reactions Gastrointestinal irritation may occur, especially in animals with pre-existing gastrointestinal disease. Such irritation may be clinically manifested by production of black faeces due to bleeding in the gastrointestinal tract. Inhibition of normal blood clotting may occur incidentally. This effect is reversible and diminishes within approximately 7 days. Use during pregnancy and lactation The use is not recommended during pregnancy and lactation because laboratory studies in rats have shown evidence of teratogenic and foetotoxic effects. Salicylic acid crosses the placenta and is excreted with the milk. Half-life in the newborn is longer and thus toxicity symptoms may occur much sooner. Furthermore, platelet aggregation is inhibited and bleeding time increased, which is not favourable during difficult parturition/caesarean section. Finally, some studies indicate that parturition is postponed. Interactions Concurrent administration of potentially nephrotoxic drugs (e.g. aminoglycosides) should be avoided. Salicylic acid is highly plasma (albumin) bound and competes with a variety of compounds (e.g. ketoprofen) for plasma protein binding sites. Plasma clearance of salicylic acid has been reported to increase in combination with corticosteroids, possibly due to induction of metabolism of salicylic acid. Concurrent use with other NSAIDs is not recommended, because of increased risk of gastrointestinal ulceration. Drugs which affect blood clotting should not be used in combination with sodium salicylate.
Vat Rate: 20%